Monoclonal Antibody-Based Candidate Therapeutics Against HIV Type 1
نویسندگان
چکیده
منابع مشابه
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In compa...
متن کاملExploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.
The HIV field has seen an increased interest in novel cure strategies. In particular, new latency reversal agents are in development to reverse latency to flush the virus out of its hiding place. Combining these efforts with immunotherapeutic approaches may not only drive the virus out of latency, but allow for the rapid elimination of these infected cells in a "shock and kill" approach. Beyond...
متن کامل1086 Monoclonal Antibody Against
Immune response (Ir) loci that map in the I region of the H-2 gene complex regulate the capacity to generate an immune response against numerous foreign antigens (1). Loci that map in the I region also control polymorphic~cell surface antigens that are expressed in immunocompetent cells (I-region-associated antigens or Ia loci) (2) and antigens that stimulate T cell proliferative responses betw...
متن کاملThe Antibody Response against HIV-1.
Neutralizing antibodies (NAbs) typically play a key role in controlling viral infections and contribute to the protective effect of many successful vaccines. In the case of HIV-1 infection, there is compelling data in experimental animal models that NAbs can prevent HIV-1 acquisition, although there is no similar data in humans and their role in controlling established infection in humans is al...
متن کاملAntibody-based therapeutics against components of the IGF system
The insulin-like growth factor I (IGF-I) receptor (IGF-1R) is overexpressed in most human neoplasms tested so far. Many tumors in young patients produce high levels of the IGF-1R ligands, IGF-I and IGF-II. Given the complexity of the IGF signaling pathway, its complete inhibition may require combination therapies with antibodies targeting both IGF-1R and IGF-II.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: AIDS Research and Human Retroviruses
سال: 2012
ISSN: 0889-2229,1931-8405
DOI: 10.1089/aid.2011.0226